The only notable exception is represented by the potential use of a glucosylceramide synthase inhibitor, GZ667161, for the treatment of PD patients associated with mutations of the gene encoding for the glucocerebrosidase (Sardi et al., 2017). This evidence concerns the gene UGCG and Parkinson disease.